Staar Surgical Company ((STAA)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Staar Surgical’s latest earnings call painted a picture of a company in the midst of a sharp turnaround. Management highlighted triple‑digit revenue growth, a return to profitability, and expanding margins, while acknowledging pricing pressure, geopolitical headwinds, and heavy dependence on China that still warrant caution for investors.
Explosive Revenue Growth Led by China
Net sales surged to $93.5 million in Q1 2026, up 119.6% year over year, as demand rebounded strongly. China was the main engine, contributing $47.4 million, or just over half of total sales, while the rest of the world grew a more modest 6%.
Adjusted EBITDA Swings Back to Profit
Profitability metrics showed a dramatic improvement, with adjusted EBITDA reaching $24.4 million compared with a loss of $26.3 million a year earlier. Management credited the turnaround to higher volumes and aggressive cost actions implemented over the past year.
Margins and Bottom Line Rebound Sharply
Gross margin expanded to 73.6% from 65.8%, while operating income flipped to an $8.0 million profit from a $57.4 million loss. Net income improved to $5.2 million, or $0.10 per diluted share, versus a $54.2 million loss and $1.10 per share deficit last year.
U.S. Market Shows Early Traction
The U.S. business delivered more than $6 million in net sales, up 22% year over year, signaling steady progress in a key strategic market. The FDA’s decision to extend EVO ICL indications to patients aged 45–60 should further widen the company’s domestic addressable base.
Product Launches and Swiss Scale-Up
Staar surpassed 4 million ICLs sold globally and launched the EVO+ lens in China, where early demand is running ahead of expectations. The Nidau, Switzerland facility is being scaled to supply all EVO and EVO+ lenses to China by 2026, a move designed to sidestep import tariffs and support growth.
China Inventory Levels Back in Balance
Management emphasized that distributor inventories in China have normalized and now sit near six months, consistent with contractual targets. Sales into the channel are now roughly aligned with end‑market demand, easing fears of overstocking and artificial growth.
Cost Discipline Drives Leaner Operating Base
Total operating expenses fell to $60.9 million from $85.4 million a year earlier, reflecting restructuring and tighter spending. Excluding special items, OpEx declined 18% to $51.5 million, and the company reiterated its 2026 annual spend target of $225 million.
Solid Cash Reserves and Debt-Free Balance Sheet
Staar ended the quarter with $163.9 million in cash, equivalents, and investments and reported no outstanding debt, providing a buffer against volatility. Management expects cash to rebuild over the remainder of the year as seasonal factors fade and profitability improves.
ERP Rollout and Efficiency Initiatives
The rollout of an Oracle ERP system is progressing with limited disruption, supporting better control across the business. Management is also focused on leveraging cost reductions started in 2025 and scaling Swiss manufacturing to capture operating leverage.
Geopolitical Headwinds Temper Ex-China Growth
Geopolitical and trade disruptions weighed on parts of the Middle East and India, trimming less than $2 million from quarterly sales. These regions remain weak and helped keep ex‑China growth muted, underscoring the company’s sensitivity to regional tensions.
Pricing Pressure Erodes ASPs
The company noted broad pricing pressure, with average selling prices down by a high single‑digit percentage globally due to mix and competition. While EVO+ is positioned as a premium lens, management acknowledged that certain markets continue to face pricing challenges.
Inventory and Manufacturing Costs Still a Drag
Gross margin gains were partially offset by higher per‑unit manufacturing costs stemming from lower 2025 production volumes. Higher‑cost inventory rolling through the income statement, provisions, and expiring product from prior years remain near‑term profitability headwinds.
Seasonal Cash Outflows Hit Q1
Cash balances declined sequentially from Q4 2025, reflecting seasonal bonuses, global sales meetings, severance, and cooperation‑related costs. Management nonetheless expects to generate cash in subsequent quarters as one‑time payments subside and earnings rise.
Limited Visibility on Product Mix and China Detail
Management declined to quantify EVO+ as a percentage of China revenue or provide granular distributor and backlog data. The lack of detailed product and regional breakdowns leaves investors with less clarity when modeling seasonality and near‑term demand.
China Concentration Remains a Key Risk
With China accounting for roughly half of Q1 sales, Staar’s fortunes are tightly tied to that market. Any regulatory changes, competitive shifts, or macro slowdown in China could significantly affect results, even as the company works to grow other regions.
Guidance: Strong Q1, but Cautious Outlook
Management declined to provide formal full‑year revenue guidance, citing macro, currency, and geopolitical uncertainty as well as unclear Q2–Q3 seasonality. Instead, it pointed to Q1’s strong results and reiterated 2026 goals of about $225 million in spending and gross margins near 75%, with more specific guidance to come once visibility improves.
Staar Surgical’s call showcased a business that has executed a swift financial turnaround, driven by China, new products, and disciplined costs. Yet pricing pressure, geopolitical risks, and market concentration mean investors should balance optimism about profitability momentum with respect for the remaining uncertainties.